论文部分内容阅读
[目的]观察多西他赛单药周给药一线治疗老年晚期非小细胞肺癌的临床疗效。[方法]30例老年晚期非小细胞肺癌初治患者予以多西他赛35mg/m2,于第1、8d给药,每21d为1个周期。[结果]30例可评价病例中,完全缓解1例,部分缓解7例,总有效率为26.3%,中位无进展生存期3.5个月,中位生存期7.8个月,1年生存率33.3%。毒副反应以粒细胞减少、乏力、脱发为主。[结论]多西他赛单药周给药一线治疗老年晚期非小细胞肺癌是安全有效的。
[Objective] To observe the clinical efficacy of docetaxel in single-week treatment of senile advanced non-small cell lung cancer. [Method] 30 patients with newly diagnosed advanced non-small cell lung cancer were treated with Docetaxel 35mg / m2, administered on the 1st and the 8th day, and each cycle was 1 cycle. [Results] Among the 30 evaluable cases, 1 was completely relieved, 7 were partially relieved, the total effective rate was 26.3%, the median progression-free survival was 3.5 months, the median survival was 7.8 months, and the 1-year survival rate was 33.3 %. Toxicity to neutropenia, fatigue, hair loss-based. [Conclusion] Docetaxel monotherapy for first-line treatment of advanced non-small cell lung cancer is safe and effective.